Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Donor immune cells tested as new weapon against tough childhood cancers

NCT ID NCT03420963

Summary

This early-stage study tested a new combination treatment for children and young adults whose solid tumors had returned or stopped responding to standard therapies. Researchers gave patients chemotherapy followed by immune cells (called NK cells) donated from umbilical cord blood to see if the combination was safe and could fight the cancer. The main goal was to find the safest dose and understand the side effects, as this was a first-in-human trial for this specific approach.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MALIGNANT SOLID NEOPLASM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.